Literature DB >> 8155250

Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg.

P L Masson1.   

Abstract

Many mechanisms can explain the mode of action of IVIg in immune disorders. Macrophage blockade and interference in the idiotypic network are supported by some experimental data. Among the other mechanisms, two are considered in greater detail. Firstly, in some disorders, the patients could improve simply because the infused Ig contains antibodies directed against the infectious antigen causing the disease. Secondly, one can expect that IVIg increases the IgG catabolism and therefore the elimination of the autoantibodies. When the concentration of IgG in the plasma reaches 200% of the normal value, for example, the fractional catabolic rate increases up to 180% of its normal value. In other words, the half-life of IgG is decreased from 21 days to 12 days.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8155250     DOI: 10.1006/jaut.1993.1057

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  9 in total

Review 1.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Variability of the inhibition by total immunoglobulin of in vitro autoantibody-mediated erythrophagocytosis by mouse macrophages.

Authors:  S Léonard; I Pierard; T E Michaelsen; S Izui; P L Masson; J-P Coutelier
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 3.  Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

4.  Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases.

Authors:  Ning Li; Minglang Zhao; Julio Hilario-Vargas; Phillip Prisayanh; Simon Warren; Luis A Diaz; Derry C Roopenian; Zhi Liu
Journal:  J Clin Invest       Date:  2005-11-10       Impact factor: 14.808

5.  The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease.

Authors:  Shreeram Akilesh; Stefka Petkova; Thomas J Sproule; Daniel J Shaffer; Gregory J Christianson; Derry Roopenian
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

6.  Intravenous immunoglobulin treatment in chronic neurological diseases: do we have maintenance dose right?

Authors:  Ondrej Dolezal
Journal:  Autoimmune Dis       Date:  2014-12-18

7.  Outcome of Intravenous Immunoglobulin-Transmitted HTLV-I, Hepatitis B, Hepatitis C, and HIV infections.

Authors:  Mohsen Foroughipour; Farahzad Jabbari Azad; Reza Farid Hosseini; Abbas Shirdel; Amir Reza Khalighi; Hadis Yousefzadeh; Homa Sadri; Toktam Moghiman; Hossein Hekmatkhah
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

Review 8.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

Review 9.  Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease.

Authors:  Elizabeth A Fitzpatrick; Jin Wang; S E Strome
Journal:  Front Immunol       Date:  2020-03-25       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.